- Home
- LZB vs AKRO Comparison
LZB vs AKRO Comparison
Compare LZB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZB
- AKRO
- Stock Information
- Founded
- LZB 1927
- AKRO 2017
- Country
- LZB United States
- AKRO United States
- Employees
- LZB N/A
- AKRO N/A
- Industry
- LZB Home Furnishings
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- LZB Consumer Discretionary
- AKRO Health Care
- Exchange
- LZB Nasdaq
- AKRO Nasdaq
- Market Cap
- LZB 1.8B
- AKRO 2.0B
- IPO Year
- LZB N/A
- AKRO 2019
- Fundamental
- Price
- LZB $43.55
- AKRO $28.24
- Analyst Decision
- LZB Hold
- AKRO Strong Buy
- Analyst Count
- LZB 1
- AKRO 8
- Target Price
- LZB N/A
- AKRO $46.83
- AVG Volume (30 Days)
- LZB 342.4K
- AKRO 608.1K
- Earning Date
- LZB 02-18-2025
- AKRO 02-27-2025
- Dividend Yield
- LZB 2.02%
- AKRO N/A
- EPS Growth
- LZB 4.44
- AKRO N/A
- EPS
- LZB 2.90
- AKRO N/A
- Revenue
- LZB $2,070,500,000.00
- AKRO N/A
- Revenue This Year
- LZB $3.32
- AKRO N/A
- Revenue Next Year
- LZB $3.97
- AKRO N/A
- P/E Ratio
- LZB $14.99
- AKRO N/A
- Revenue Growth
- LZB N/A
- AKRO N/A
- 52 Week Low
- LZB $32.00
- AKRO $15.32
- 52 Week High
- LZB $46.47
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- LZB 49.12
- AKRO 42.96
- Support Level
- LZB $42.25
- AKRO $27.45
- Resistance Level
- LZB $44.05
- AKRO $28.76
- Average True Range (ATR)
- LZB 1.12
- AKRO 1.44
- MACD
- LZB -0.15
- AKRO -0.08
- Stochastic Oscillator
- LZB 34.38
- AKRO 21.92
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.